Distinguishing Kikuchi-Fujimoto Disease from Lymphoma in Patients by Clinical and PET/CT Features

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 Apr 19

PMID 38640333

Authors

Mu-Hua Cheng

Liang-Jun Xie

Affiliations

Soon will be listed here.

Abstract

To develop a scheme for distinguishing Kikuchi-Fujimoto disease (KFD) from lymphoma in patients presenting enlarged lymph nodes (LNs) predominantly on the upper side of the diaphragm. From November 2015 to August 2023, 32 KFD patients and 38 lymphoma patients were pathologically confirmed and enrolled in this retrospectively study. Clinical and 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) features were collected. When comparing those PET/CT parameters, we set 5 models with different research objects: (1) all affected LNs; (2) the 5 largest affected LNs in terms of maximum diameter; (3) the 5 largest affected LNs in terms of maximum standard uptake values (SUVmax); (4) the largest affected LNs in terms of maximum diameter; (5) the largest affected LNs in terms of SUVmax. Compared to lymphoma patients, KFD patients were younger; and with higher incidence of fever, arthralgia, abnormal serum white blood cell, lactate dehydrogenase (LDH) and splenomegaly; lower incidence of affected LNs perinodal infiltration, necrosis and conglomeration; more affected LNs in Head and Neck nodes (particularly in level II) and Axillary in KFD (P ˂ .05). PET/CT parameters presented as various difference in each model. Finally, 11 clinical and PET/CT features (age ≤ 34, with fever, arthralgia, abnormal white blood cell, abnormal LDH, and without node necrosis and node conglomeration have a score of 2 each; splenomegaly, perinodal infiltration, median maximum diameter ≤ 20.5 and median SUVmax ≤ 7.1 of affected LNs in model 2 have score of 1 each) were selected as scheme items for distinguishing KFD from lymphoma. Individuals who have a total score > 8, meet the criteria for KFD. Sensitivity and specificity were high: 86.8% (95% CI: 71.9%, 95.5%) and 96.9% (95% CI: 83.7%, 99.5%), AUC = 0.975 (95% CI: 90.5%, 99.6%), respectively. It can effectively distinguish KFD from lymphoma by clinical and PET/CT parameters.

References

Kwon S, Kim T, Kim Y, Lee K, Lee N, Seol H . CT findings in Kikuchi disease: analysis of 96 cases. AJNR Am J Neuroradiol. 2004; 25(6):1099-102. PMC: 7975664. View

Shim E, Lee K, Kim E, Kim H, Jang J . CT pattern analysis of necrotizing and nonnecrotizing lymph nodes in Kikuchi disease. PLoS One. 2017; 12(7):e0181169. PMC: 5524397. DOI: 10.1371/journal.pone.0181169. View

Bosch X, Guilabert A, Miquel R, Campo E . Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. Am J Clin Pathol. 2004; 122(1):141-52. DOI: 10.1309/YF08-1L4T-KYWV-YVPQ. View

Perry A, Choi S . Kikuchi-Fujimoto Disease: A Review. Arch Pathol Lab Med. 2018; 142(11):1341-1346. DOI: 10.5858/arpa.2018-0219-RA. View

Wang S, Du B, Li X, Li Y . Positron emission tomography/computed tomography hypermetabolism of Kikuchi-Fujimoto disease mimicking malignant lymphoma: a case report and literature review. J Int Med Res. 2021; 49(7):3000605211032859. PMC: 8326629. DOI: 10.1177/03000605211032859. View

Aoyama K, Otsuru M, Uchibori M, Ota Y . Kikuchi-Fujimoto Disease with 18F-Fludeoxyglucose Uptake in Cervical Lymph Nodes on Dual-time-point Imaging Positron Emission Tomography/Computed Tomography Mimicking Malignant Disease. World J Nucl Med. 2017; 16(1):68-70. PMC: 5314668. DOI: 10.4103/1450-1147.174712. View

Mathew L, Kapila R, Schwartz R . Kikuchi-Fujimoto disease: a diagnostic dilemma. Int J Dermatol. 2016; 55(10):1069-75. DOI: 10.1111/ijd.13314. View

Baek H, Lee J, Lim H, Lee H, Baek J . Diagnostic accuracy of the clinical and CT findings for differentiating Kikuchi's disease and tuberculous lymphadenitis presenting with cervical lymphadenopathy. Jpn J Radiol. 2014; 32(11):637-43. DOI: 10.1007/s11604-014-0357-2. View

Kong E, Chun K, Hong Y, Hah J, Cho I . 18F-FDG PET/CT findings in patients with Kikuchi disease. Nuklearmedizin. 2013; 52(3):101-6. DOI: 10.3413/Nukmed-0513-12-06. View

10.

Deaver D, Horna P, Cualing H, Sokol L . Pathogenesis, diagnosis, and management of Kikuchi-Fujimoto disease. Cancer Control. 2014; 21(4):313-21. DOI: 10.1177/107327481402100407. View

11.

Ito K, Morooka M, Kubota K . Kikuchi disease: 18F-FDG positron emission tomography/computed tomography of lymph node uptake. Jpn J Radiol. 2010; 28(1):15-9. DOI: 10.1007/s11604-009-0375-7. View

12.

Miller Jr W . Cross-sectional imaging of Kikuchi disease. J Comput Assist Tomogr. 1999; 23(4):548-51. DOI: 10.1097/00004728-199907000-00011. View

13.

Hutchinson C, Wang E . Kikuchi-Fujimoto disease. Arch Pathol Lab Med. 2010; 134(2):289-93. DOI: 10.5858/134.2.289. View

14.

Som P, Curtin H, Mancuso A . Imaging-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol. 2000; 174(3):837-44. DOI: 10.2214/ajr.174.3.1740837. View

15.

Lewis W, Lilly S, Jones K . Lymphoma: Diagnosis and Treatment. Am Fam Physician. 2020; 101(1):34-41. View

16.

Tsujikawa T, Tsuchida T, Imamura Y, Kobayashi M, Asahi S, Shimizu K . Kikuchi-Fujimoto disease: PET/CT assessment of a rare cause of cervical lymphadenopathy. Clin Nucl Med. 2011; 36(8):661-4. DOI: 10.1097/RLU.0b013e31821a2878. View

17.

Pepe F, Disma S, Teodoro C, Pepe P, Magro G . Kikuchi-Fujimoto disease: a clinicopathologic update. Pathologica. 2017; 108(3):120-129. View